INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 54 filers reported holding INOZYME PHARMA INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,238,294 | -24.6% | 2,437,689 | 0.0% | 0.79% | -23.6% |
| Q2 2023 | $13,577,928 | -2.8% | 2,437,689 | 0.0% | 1.04% | +7.2% |
| Q1 2023 | $13,967,958 | +445.7% | 2,437,689 | 0.0% | 0.97% | +570.8% |
| Q4 2022 | $2,559,573 | -60.9% | 2,437,689 | -0.3% | 0.14% | -56.0% |
| Q3 2022 | $6,551,000 | -37.6% | 2,444,379 | 0.0% | 0.33% | -39.3% |
| Q2 2022 | $10,494,000 | +5.0% | 2,444,379 | 0.0% | 0.54% | +86.5% |
| Q1 2022 | $9,997,000 | -40.0% | 2,444,379 | 0.0% | 0.29% | -14.2% |
| Q4 2021 | $16,671,000 | -41.2% | 2,444,379 | 0.0% | 0.34% | 0.0% |
| Q3 2021 | $28,330,000 | -32.0% | 2,444,379 | 0.0% | 0.34% | -37.9% |
| Q2 2021 | $41,652,000 | -13.9% | 2,444,379 | 0.0% | 0.54% | -50.0% |
| Q1 2021 | $48,399,000 | -4.1% | 2,444,379 | 0.0% | 1.09% | -18.5% |
| Q4 2020 | $50,452,000 | -21.5% | 2,444,379 | 0.0% | 1.33% | -51.0% |
| Q3 2020 | $64,263,000 | – | 2,444,379 | – | 2.72% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |